Intracavernous pharmacotherapy for erectile dysfunction

@article{Bella2004IntracavernousPF,
  title={Intracavernous pharmacotherapy for erectile dysfunction},
  author={Anthony J. Bella and Gerald B. Brock},
  journal={Endocrine},
  year={2004},
  volume={23},
  pages={149-155}
}
With the advent of phosphodiesterase type-5 inhibition as oral therapy, intracavernous injection of vasoactive agents has been relegated to second-line therapy for most patients with erectile dysfunction. However, the future of this category of agents remains bright as an ever-expanding number and combination of agents in use and under investigation will likely make intracavernous injection more appealing as greater efficacy, tolerability, and more rapid onset is attained. In this article… 

Pharmacotherapy of erectile dysfunction

Yohimbin acts via central alpha-receptor blockade and showed a significant effect in a recent double blind study compared to placebo, and the centrally acting substances Apomorphin and Trazodone were also tested for their potential use with Apomorphicin showing promising results.

Phosphodiesterase 5 inhibitors and erectile dysfunction

The use of PDE5 inhibitors within other indications beyond erectile dysfunction has become an important new aspect in the development of these drugs and will have a substantial influence on research and development within this unique class of drugs.

The promise of inhibition of smooth muscle tone as a treatment for erectile dysfunction: where are we now?

The various pathways involved in the maintenance of penile smooth muscle tone are outlined and the current potential benefit for the pharmacological inhibition of these targets for the treatment of ED is discussed.

Emerging drugs for the treatment of erectile dysfunction

The paper will examine the “second-generation” phosphodiesterase 5-inhibitors, soluble guanylate cyclases, rho-kinase inhibitors, and maxi-k channel activators that act peripherally, and the potential agents that target them.

Erectile dysfunction in the aging man: current options for treatment

Penile prosthesis implantation has the highest rate of success but is reserved as a final treatment option due to cost, invasiveness and irreversibility, and Gene therapy for erectile dysfunction is in the early stages of investigation.

Current Perspectives on Pharmacotherapy Treatments for Erectile Dysfunction

As the world’s older population increases, it is estimated that the prevalence of ED will double from 152 million men in 1995 to 322 millionMen in 2025, indicating a dire need to reevaluate current ED therapeutic strategies.

Optoelectronic method for increasing the sensibility of mass spectrometer in the case of the determination of papaverine

Papaverine is an opiate alkaloid used in the primary treatment of visceral spasms, cardiac and cerebral vasospasms, and occasionally for the treatment of erectile dysfunction, but its use for the latest recommendations should be regarded with caution.

channel therapeutics at the bedside

KATP channel openers have a unique therapeutic spectrum, ranging from applications in myopreservation and vasodilatation in patients with heart or vascular disease to potential clinical use as bronchodilators, bladder relaxants, islet cell protector, antiepileptics and promoters of hair growth.

Focused issue on KATP channels K ATP channel therapeutics at the bedside

KATP channel openers have a unique therapeutic spectrum, ranging from applications in myopreservation and vasodilatation in patients with heart or vascular disease to potential clinical use as bronchodilators, bladder relaxants, islet cell protector, antiepileptics and promoters of hair growth.

References

SHOWING 1-10 OF 72 REFERENCES

New directions for erectile dysfunction therapies

Some directions for future erectile dysfunction therapies can be identified, and strategies to prevent cavernosal degeneration and/or to restore cavernosal function will be one of the most exciting challenges for future research.

Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction

  • H. Porst
  • Medicine
    International Journal of Impotence Research
  • 2000
A historical and current perspective on intracavernosal therapy is provided and the popular injectable therapeutic agents that are currently used for the treatment of ED are reviewed.

Progressive treatment of erectile dysfunction with intracorporeal injections of different combinations of vasoactive agents

Using the progressive method, by starting with the most available and inexpensive drugs, patients with erectile dysfunction can be given optimal treatment according to the severity of their disease, the success rate is high while costs are kept to a minimum.

EFFICACY AND SAFETY OF INTRACAVERNOSAL ALPROSTADIL IN MEN WITH ERECTILE DYSFUNCTION

The efficacy and safety of alprostadil formulated for intracavernosal treatment in men with erectile dysfunction of vasculogenic, neurogenic, psychogenic, and mixed causes were investigated in three separate multi-institutional, prospective studies.

Intracavernous injections: still the gold standard for treatment of erectile dysfunction in elderly men

If this form of therapy is chosen for aged men the triple combination therapy (PPR) yields a higher response rate than that obtained with prostaglandin alone, and a statistically significant association between the results obtained after the injection of PPR as compared to PE.

Intracavernosal therapy: When oral agents fail

  • A. Nehra
  • Medicine
    Current urology reports
  • 2001
Injection therapy has been used safely and successfully by many men and their partners since its original description in the early 1980s, and early reports of patient satisfaction and reproducibility of erectile rigidity have not matched those of intracavernosal therapy.
...